Mainz Biomed (NASDAQ:MYNZ) Short Interest Update

Mainz Biomed (NASDAQ:MYNZ) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 101,700 shares, a growth of 190.6% from the January 31st total of 35,000 shares. Based on an average daily trading volume, of 203,700 shares, the days-to-cover ratio is currently 0.5 days. Currently, 5.4% of the shares of the company are sold short.

Institutional Investors Weigh In On Mainz Biomed

A hedge fund recently bought a new stake in Mainz Biomed stock. Virtu Financial LLC purchased a new stake in Mainz Biomed (NASDAQ:MYNZ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned 0.92% of Mainz Biomed at the end of the most recent reporting period.

Mainz Biomed Stock Down 13.4 %

Mainz Biomed stock traded down $0.81 on Friday, hitting $5.23. The company’s stock had a trading volume of 191,462 shares, compared to its average volume of 243,598. The firm has a market cap of $10.47 million, a P/E ratio of -0.08 and a beta of 0.32. The company has a fifty day moving average price of $5.38 and a 200-day moving average price of $8.70. Mainz Biomed has a one year low of $3.65 and a one year high of $45.60.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MYNZ shares. HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th. Maxim Group started coverage on shares of Mainz Biomed in a research note on Friday, February 14th. They set a “buy” rating and a $14.00 target price for the company.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.